AAV-Dok7 gene therapy suppresses motor nerve terminal degeneration at NMJs, mitigates muscle atrophy, and enhances motor activity and lifespan through tail vein injection at age 90 days (symptomatic stage) in the SOD1 G93A-ALS mouse model. Here, SOD1 is linked to amyotrophic lateral sclerosis.